arrow
N

Nicolas Girard

Institut Curie
H指数:81
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

TROP2的归一化膜比作为datopotamab deruxtecan在非小细胞肺癌中预测临床结局的指标

2026-11-110
OA
Elizabeth Anne Leece, BVSc, Cert VA, Dip ECVAA, MRCVS (1970-2025) Obituary

伊丽莎白·安妮·利斯,BVSc,Cert VA,Dip ECVAA,MRCVS(1970-2025)讣告

2026-01-010
PRE
Cardiovascular safety of a standardized outpatient triage and diagnostic approach for suspected cardiovascular immune-related adverse events of immune checkpoint inhibitors

Cribari F,Hamdi I,Henriquez S,Joulia M-L,Charles P,Colle R,等。免疫检查点抑制剂疑似心血管免疫相关不良事件的标准门诊分诊和诊断方法的心血管安全性。Arch Cardiovasc Dis. (2025) 118(6–7):S1875-2136(25)00402-4. doi: 10.1016/j.acvd.2025.06.073。

2025-12-011
PRE
Real-World Characteristics, Treatment Patterns, and Outcomes in Advanced HER2 (ERBB2)-Mutant Non-Small Cell Lung Cancer: A Retrospective Study of Single Centers in France and Germany

真实世界特征、治疗模式及结局:HER2 (ERBB2)突变型晚期非小细胞肺癌的法国和德国单中心回顾性研究

2025-11-010
OAAI
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

纳入临床试验的可切除III期非小细胞肺癌(NSCLC)定义:由EORTC肺癌组领导的泛欧洲多学科专家小组的临床病例回顾

2025-10-140
PRE
Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis

新辅助纳武利尤单抗联合铂类化疗治疗可切除肺癌的手术结果。一项多中心欧洲真实临床实践分析

2025-10-010
PRE
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer

Sevabertinib治疗晚期HER2-Mutant非小细胞肺癌

2025-10-014
PRE
International Thymic Malignancy Interest Group Standard Definitions, Policies, and Reporting Measures for Thymic Epithelial Tumors

国际胸腺恶性病变兴趣小组:胸腺上皮性肿瘤的标准定义、政策及报告措施

2025-09-260
PRE
Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study

法国真实世界中晚期非小细胞肺癌患者使用纳武利尤单抗的治疗及免疫治疗再挑战结局:LIST研究中期结果

2025-09-140
OAAI
Sparing effects of FLASH irradiation in patient-derived lung tissue

FLASH照射对病人来源肺组织的保护作用

2025-09-060
OAAI
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial

仑伐替尼联合帕博利珠单抗治疗经治性转移性B3胸腺瘤和胸腺癌(PECATI):一项单臂、II期临床试验

2025-09-010
PRE
Response to letter Re: “Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS”

回复函:关于“吗啡和二甲双胍影响非小细胞肺癌患者免疫治疗效果:IFCT-1502 CLINIVO-SNDS真实世界研究的结果”

2025-07-300
PRE
AFSOS-SFRO guidelines on radiation-induced lung injury

放射性肺损伤AFSOS-SFRO指南

2025-07-170
PRE
Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA

拉泽替尼与奥希替尼在先前未经治疗的EGFR突变晚期NSCLC中的比较: 来自MARIPOSA的随机,双盲,探索性分析

2025-07-030
OAAI
Clinical outcomes of compound EGFR mutations in non-small cell lung cancer: A national, retrospective, multicenter study.

非小细胞肺癌中复合EGFR突变的治疗效果:一项全国性、回顾性、多中心研究。

2025-06-250
PREAI
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS

吗啡和二甲双胍影响NSCLC患者免疫治疗效果:IFCT-1502 CLINIVO-SNDS真实世界研究的结果

2025-06-110
PRE
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer

EVOKE-01研究:沙库巴曲韦他尼 vs 多西他赛在非小细胞肺癌患者中的疗效对比的简明摘要

2025-05-150
OA